Abiopharma

Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer: Disclosure of Changes in Interest of Director

Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer: Disclosure of Changes in Interest of Director

Employee Stock Option/ Share Scheme: Lapse of Awards under Share Grant Plan

Novo Nordisk’s Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular diseas

Windows Security Not Opening: Repair Guide

What To Do If Logitech G Hub Is Not Opening

The Top Tools For Personal Financial Planning Software (2025)

Best Laptops for College Students in 2025

Computer Drivers: A Complete Guide

Alnylam promuoverà Zilebesiran in un trial clinico globale di fase 3 basato sui risultati cardiovascolari

Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial

Baxdrostat demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with hard-to-control hype

New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups

Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension